[SCHEDULE 13G/A] ADC Therapeutics SA SEC Filing

Rhea-AI Filing Summary

Redmile Group and affiliated entities report significant holdings in ADC Therapeutics SA. The Schedule 13G/A discloses that Redmile Group, LLC and Jeremy C. Green collectively have shared voting and dispositive power over 15,666,731 common shares, representing 14.0% of the outstanding common stock on the basis described in the filing. One affiliated fund, RedCo II Master Fund, L.P., is reported with shared power over 13,145,712 shares (11.7%). The filing states these shares are held by private investment vehicles managed by Redmile and that both Redmile Group and Mr. Green disclaim direct beneficial ownership except to the extent of any pecuniary interest. The percentage calculations use the issuer's reported outstanding shares plus a recent private placement.

Positive

• Significant institutional stake: Redmile-affiliated holders report shared power over 15,666,731 shares, representing 14.0% of common stock.
• Clear disclosure of ownership structure: Filing identifies Redmile Group, Jeremy C. Green, and RedCo II Master Fund and explains that holdings are through managed private investment vehicles.
• Compliance with reporting rules: The filer used Schedule 13G/A format and included certification that holdings were not acquired to change control.

Negative

• None.

Insights

Financial Analyst

TL;DR Redmile's disclosed ~14% position is material and may influence market perception of ADC Therapeutics' shareholder base.

The filing shows Redmile-affiliated vehicles control shared voting and dispositive power over 15,666,731 ADS common shares (reported as 14.0%). For investors, an active 10%+ stake by an institutional investment adviser signals a potentially influential holder but the filing includes disclaimers limiting asserted beneficial ownership. The separation between legal ownership (funds) and adviser control is typical for investment managers; materiality arises from size alone rather than any stated intent to seek control or nominate directors. Impact on valuation depends on whether Redmile increases, decreases, or engages with management.

Corporate Governance Expert

TL;DR A disclosed >10% position requires monitoring but the filer disclaims control; no explicit governance actions are announced.

The Schedule 13G/A classifies the disclosure as passive holdings by investment vehicles managed by Redmile, with Redmile and Jeremy C. Green disclaiming beneficial ownership except for pecuniary interest. The statement's certification affirms the securities were not acquired to change or influence control. From a governance perspective, the filing does not indicate activist intent or proposals. Stakeholders should note the size and that pre-funded warrants with exercise limits were excluded from the reported counts, which constrains immediate dilution or threshold breaches.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

ADC Therapeutics SA

(Name of Issuer)

Common Shares, par value CHF 0.08 per share

(Title of Class of Securities)

H0036K147

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. H0036K147

1

Names of Reporting Persons

Redmile Group, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 15,666,731.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,666,731.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,666,731.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.0 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Redmile Group, LLC's beneficial ownership of the Issuer's common shares ("Common Stock") is comprised of 15,666,731 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC (collective, the "Redmile Clients"), including RedCo II Master Fund, L.P. ("RedCo II"), which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on the sum of (i) 99,178,286 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in its Form 10-Q for the quarterly period ended March 31, 2025 filed with the Securities and Exchange Commission (the "SEC") on May 14, 2025 (the "Form 10-Q"); plus (ii) 13,031,161 shares of Common Stock issued by the Issuer in a private placement as of June 16, 2025, as reported by the Issuer in its Form 8-K filed with the SEC on June 12, 2025 (the "Form 8-K").

SCHEDULE 13G

CUSIP No. H0036K147

1

Names of Reporting Persons

Jeremy C. Green

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 15,666,731.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,666,731.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,666,731.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Jeremy C. Green's beneficial ownership of the Common Stock is comprised of 15,666,731 shares of Common Stock owned by the Redmile Clients, including RedCo II, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on the sum of (i) 99,178,286 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 13,031,161 shares of Common Stock issued by the Issuer in a private placement as of June 16, 2025, as reported by the Issuer in the Form 8-K.

SCHEDULE 13G

CUSIP No. H0036K147

1

Names of Reporting Persons

RedCo II Master Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,145,712.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,145,712.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,145,712.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.7 %

12

Type of Reporting Person (See Instructions)

PN, FI

Comment for Type of Reporting Person: Percentage based on the sum of (i) 99,178,286 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 13,031,161 shares of Common Stock issued by the Issuer in a private placement as of June 16, 2025, as reported by the Issuer in the Form 8-K.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ADC Therapeutics SA
(b)	Address of issuer's principal executive offices: Biopole, Route de la Corniche 3B, 1066 Epalinges, Switzerland
Item 2.
(a)	Name of person filing: Redmile Group, LLC Jeremy C. Green RedCo II Master Fund, L.P.
(b)	Address or principal business office or, if none, residence: Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 RedCo II Master Fund, L.P. c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129
(c)	Citizenship: Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom RedCo II Master Fund, L.P.: Cayman Islands
(d)	Title of class of securities: Common Shares, par value CHF 0.08 per share
(e)	CUSIP No.: H0036K147
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Redmile Group, LLC - 15,666,731 (1) Jeremy C. Green - 15,666,731 (1) RedCo II Master Fund, L.P. - 13,145,712 (2)
(b)	Percent of class: Redmile Group, LLC - 14.0% (3) Jeremy C. Green - 14.0% (3) RedCo II Master Fund, L.P. - 11.7% (3)
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Redmile Group, LLC - 0 Jeremy C. Green - 0 RedCo II Master Fund, L.P. - 0
	(ii) Shared power to vote or to direct the vote: Redmile Group, LLC - 15,666,731 (1) Jeremy C. Green - 15,666,731 (1) RedCo II Master Fund, L.P. - 13,145,712 (2)
	(iii) Sole power to dispose or to direct the disposition of: Redmile Group, LLC - 0 Jeremy C. Green - 0 RedCo II Master Fund, L.P. - 0
	(iv) Shared power to dispose or to direct the disposition of: Redmile Group, LLC - 15,666,731 (1) Jeremy C. Green - 15,666,731 (1) RedCo II Master Fund, L.P. - 13,145,712 (2) (1) The shares of the Issuer's Common Stock reported herein are held by certain Redmile Clients, including RedCo II, for which Redmile Group, LLC is the investment manager/adviser and, in such capacity, exercises voting and investment power over all of the shares of Common Stock held by the Redmile Clients and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the principal of Redmile Group, LLC and also may be deemed to be the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. The shares of Common Stock beneficially owned by Redmile Group, LLC and Mr. Green exclude 23,897,532 shares issuable upon the exercise of the pre-funded warrants held by certain Redmile Clients, including RedCo II, as such warrants include a provision that a holder is prohibited from exercising such warrants to the extent that, upon such exercise, the shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entity with whom the exercising holder's beneficial ownership would be aggregated for purposes of Section 13(d) under the Securities Exchange Act of 1934, as amended (the "Act"), would exceed 9.99% of the total number of shares of Common Stock outstanding immediately after giving effect to such exercise. (2) The shares of Common Stock beneficially owned by RedCo II exclude 18,599,071 shares issuable upon the exercise of the pre-funded warrants held by RedCo II, as such warrants include a provision that a holder is prohibited from exercising such warrants to the extent that, upon such exercise, the shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entity with whom the exercising holder's beneficial ownership would be aggregated for purposes of Section 13(d) under the Act, would exceed 9.99% of the total number of shares of Common Stock outstanding immediately after giving effect to such exercise. (3) Percentage based on the sum of (i) 99,178,286 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 13,031,161 shares of Common Stock issued by the Issuer in a private placement as of June 16, 2025, as reported by the Issuer in the Form 8-K.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See the response to Item 4.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Redmile Group, LLC

Signature:	/s/ Jeremy C. Green
Name/Title:	Managing Member
Date:	08/14/2025

Jeremy C. Green

Signature:	/s/ Jeremy C. Green
Name/Title:	Jeremy C. Green
Date:	08/14/2025

RedCo II Master Fund, L.P.

Signature:	/s/ Jeremy C. Green
Name/Title:	Managing Member of RedCo II (GP), LLC, general partner of RedCo II Master Fund, L.P.
Date:	08/14/2025

FAQ

How many ADC Therapeutics (ADCT) shares does Redmile Group report having voting power over?

The filing reports Redmile Group and Jeremy C. Green have shared voting power over 15,666,731 shares of ADC Therapeutics common stock.

What percentage of ADCT does RedCo II Master Fund, L.P. hold according to the filing?

RedCo II Master Fund, L.P. is reported with shared power over 13,145,712 shares, representing 11.7% of the class on the stated basis.

Does Redmile claim to beneficially own the reported ADC Therapeutics shares?

The filing states Redmile Group, LLC and Jeremy C. Green disclaim beneficial ownership of the shares except to the extent of any pecuniary interest; the shares are held by private investment vehicles managed by Redmile.

Were any pre-funded warrants included in the reported share totals?

No; the filing expressly excludes certain pre-funded warrants from the reported beneficial ownership because exercise limitations prevent exceeding specified ownership thresholds.

Does the filing indicate Redmile intends to change or influence control of ADC Therapeutics?

No; the certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.